A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

NCT03952559 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

516

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Baricitinib
DRUG: Placebo
DRUG: Topical corticosteroid

Sponsor

Eli Lilly and Company

Collaborators

[object Object]